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Abstract
Background—A pooled analysis in cardiogenic shock due to acute coronary syndromes is 
desirable to assess the effect of early revascularization (ERV) across all ages and a wide spectrum 
of disease severity.
Methods—Only two randomized controlled trials (RCT), i.e. SMASH and SHOCK, met the 
inclusion criteria and were combined for a pooled analysis using individual patient data (n = 348).
Results—SMASH patients (n = 54, 16%) had more severe disease than SHOCK patients (n = 
294, 84%). After adjustment for age, anoxic brain damage, non-inferior myocardial infarction, 
prior coronary artery bypass graft surgery, renal failure, systolic blood pressure, and selection for 
coronary angiography, one-year mortality was similar (relative risk SHOCK versus SMASH 0.87, 
95% CI: 0.61–1.25). Relative risk of one-year death for ERV versus initial medical stabilization 
was 0.82 (95% CI: 0.70–0.96). There was no significant difference in the treatment effect by age 
(≤75 years relative risk at one year 0.79, 95% CI: 0.63–0.99; >75 years relative risk at one year 
0.93, 95% CI: 0.56–1.53; interaction P = 0.10).
Conclusions—Only two RCT have been published emphasizing the difficulty of enrolling 
critically ill patients. Despite large differences in shock severity, ERV benefit is similar across all 
ages and not significantly different for the elderly.
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Introduction
Enrolling critically ill patients in randomized controlled trials (RCT) is difficult, mainly due 
to disease severity and challenges in obtaining consent (1,2). Therefore, RCT that are per 
formed in critically ill patients may show slow enrollment rates, may be terminated 
prematurely for lack of feasibility, or even may not be conducted at all (3). Consequently, 
due to a lack of data, treatment might not be applied to those patients who are the sickest and 
in greatest need (4).
Cardiogenic shock (CS) complicating acute myocardial infarction occurs in approximately 
5–7% of patients with reported mortality rates exceeding 50% (5,6). The use of an early 
invasive strategy in the setting of acute myocardial infarction complicated by CS has been 
studied in several retrospective analyses and suggested a benefit of early revascularization 
compared with no revascularization (7–12). However, only a few prospective randomized 
trials have been undertaken to investigate this issue (13–16). Slow recruitment rates were a 
common problem in RCT attempting to address this important clinical question (1), which 
led to an early termination in some (13,14,16). Owing to the relatively small number of 
events, the published RCT in ACS and CS to date have been relatively under-powered and 
failed to show differences in their primary outcomes (15,16).
Guidelines for treatment of CS give different classes for the early revascularization 
recommendation in patient’ s ≤75 and >75 years of age (17). The reason for this 
inconsistency is the apparent lack of benefit of early revascularization in the small subset of 
elderly patients in the ‘ Should we revascularize occluded coronaries for cardiogenic shock? 
(SHOCK) trial ’ (15), in contrast to the results of the SHOCK Registry (18) where elderly 
patients benefited from early invasive therapy.
Thus, the main aims of this pooled analysis are to assess the effect of early revascularization 
among a wide spectrum of disease severity in CS complicating acute myocardial infarction, 
and to examine the effect of early revascularization by age.
Patients and Methods
Study selection
A literature search using Medline, Cochrane library databases, reference lists of review 
articles (1,13,19–27), and abstract indexes of international scientific meetings was 
performed. Studies were included if they only enrolled patients with acute myocardial 
infarction complicated by CS, excluded patients with a mechanical or other cause of shock, 
and were RCT of early revascularization versus initial medical stabilization. Of 201 
screened abstracts four gave information about an RCT (Figure 1). Of these, the 
‘ Thrombolysis and angioplasty in cardiogenic shock (TACS) ’ (13) and the ‘ How effective 
are revascularization options in cardiogenic shock (HEROICS) ’ (14) trials were terminated 
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prematurely and never got published (personal communication of the principal 
investigators). Thus, only two reports, i.e. SHOCK (15) and the Swiss multicenter 
evaluation of early angioplasty for shock following myocardial infarction (SMASH) (16), 
were included in this analysis (Table I).
SMASH trial design
SMASH was a randomized controlled nine-center trial in 55 patients with CS complicating 
acute myocardial infarction (16). The trial compared an early invasive strategy with 
percutaneous coronary intervention or coronary artery bypass graft surgery if feasible with a 
conservative strategy and it was terminated early due to slow enrollment. The study protocol 
encouraged the use of intra-aortic balloon counterpulsation or other mechanical circulatory 
support devices. Inclusion criteria included
1. refractory CS over ≥30 min, defined as systolic blood pressure ≤90 mmHg despite 
inotropic support and intravenous volume administration as needed, capillary 
wedge pressure >15 mmHg and cardiac index <2.2 l/min/m2 if measured, 
associated with a compatible clinical presentation;
2. acute myocardial infarction <48 h prior to randomization defined as at least two of 
the following elements: chest pain; ST segment elevation of at least 0.1 mV in limb 
leads or 0.2 mV in precordial leads or left bundle branch block; or serum creatine-
phosphokinase MB isoenzyme elevation above twice the upper limit of normal;
3. coronary angiography technically feasible, i.e. vascular access and catheterization 
laboratory available; and
4. informed consent.
Exclusion criteria included ongoing manual cardiopulmonary resuscitation; prior cardiac 
arrest with presumed severe cerebral damage; shock not primarily cardiogenic in origin, 
mechanical complications, i.e. free wall or septum ventricular rupture, acute severe mitral 
regurgitation, or pericardial tamponade; serious non-cardiac illness contraindicating an 
invasive approach; decision to perform angiography taken before the onset of shock; or 
physician ' s choice for intervention. The primary end-point was mortality from all causes 30 
days after randomization. Secondary endpoints included all-cause mortality at one year.
SHOCK trial design
SHOCK was a randomized controlled 30-center trial comparing early revascularization and 
initial medical stabilization in 302 patients with CS after myocardial infarction (15,28–30). 
Intra-aortic balloon counterpulsation was recommended for all patients. Inclusion criteria 
included
1. ST-segment elevation myocardial infarction, a Q-wave infarction, a new left 
bundle-branch block, or a posterior infarction with anterior ST-segment depression;
2. CS defined as hypotension, i.e. a systolic blood pressure of <90 mmHg for at least 
30 min or the need for supportive measures to maintain a systolic blood pressure of 
≥90 mm Hg, a cardiac index of no more than 2.2 l/min/m2, a pulmonary-capillary 
wedge pressure of at least 15 mmHg, and end-organ hypoperfusion, i.e. cool 
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extremities or a urine output of <30 ml per hour, not due to bradycardia, e.g. a heart 
rate of ≥60 beats per min; and
3. informed consent.
Exclusion criteria included severe systemic illness, mechanical or other cause of shock, 
severe valvular disease, dilated cardiomyopathy, the inability to gain access for 
catheterization, and unsuitability for revascularization. The primary end point was all-cause 
mortality 30 days after randomization. Secondary endpoints included all-cause mortality at 
one year.
Statistical analysis
Baseline differences and raw mortality rates between the two studies included in this 
analysis were compared by Student’ s t -test for normally distributed continuous variables, 
the Wilcoxon rank-sum test for non-normally distributed continuous variables, and Fisher ' s 
exact test and χ2-test for categorical variables, where appropriate. One-year mortality was 
adjusted for confounding covariates using a Cox proportional hazards regression model. The 
Breslow-Day test of homogeneity of odds ratios was used to detect significant interactions 
between variables. With the evidence of heterogeneity between studies, a random-effects 
meta-analysis using individual patient data estimating the risk ratio was appropriate, and 
Forest plots were generated to visualize relative risks. To evaluate the effect of age on 
revascularization, we partitioned all subjects into five age groups such that there were 
approximately equal numbers of patients in each age group (≤55 n = 56, 56–65 n = 96, 66–
70 n = 54, 71–75 n = 80, and >75 n = 62), and performed a random effects meta-analysis in 
each cohort; analyses were also conducted separately for patients ≤75 years and >75 years of 
age. In addition, interaction of early revascularization and age regarding one year mortality 
was performed using Cox proportional hazards regression model. All P-values were two-
sided. A P-value <0.05 was considered statistically significant. Analyses were conducted 
using commercially available soft ware (SAS version 8.2, Cary, NC, USA and SPSS 
Version 14.0, SPSS Inc., Chicago, IL, USA).
Results
The two trials combined enrolled 357 patients, of which 302 were enrolled in SHOCK and 
55 in SMASH. Since not all patients had confirmed CS because predominant left ventricular 
failure was not verified after randomization, 9 patients (3%) with reasons for CS other than 
left ventricular dysfunction were excluded (SHOCK n = 8, SMASH n = 1) leaving 348 
(97%) patients for analysis (SHOCK n = 294, 84%, SMASH n = 54, 16%). Of the total 
population, 62 (18%) patients were ≥75 years old (SHOCK n = 53, SMASH n = 9).
SMASH patients more oft en had a history of congestive heart failure, presented more oft en 
with pulmonary edema on chest X-ray, and had a lower initial blood pressure than SHOCK 
patients (Table II). In contrast, SHOCK patients more oft en received vasopressors/inotropic 
agents, thrombolytic therapy, and intra-aortic balloon counterpulsation than SMASH 
patients did. While in SMASH no patient underwent coronary artery bypass graft surgery, 
37% of SHOCK patients who received early revascularization in that assigned group did 
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(18% overall); in contrast, the percutaneous transluminal coronary angioplasty rate was 
higher in SMASH than in SHOCK (56% versus 35%, P = 0.006).
Overall mortality was higher in SMASH than SHOCK at both 30 days (74% versus 51%, P 
= 0.003) and one year (77% versus 59%, P = 0.014). However, after adjustment for disease 
severity using an at-presentation severity score (P < 0.001) that included age, anoxic brain 
damage, non-inferior myocardial infarction, prior coronary artery bypass graft surgery, renal 
failure (defined as creatinine ≥1.9 mg/dl), and systolic blood pressure, as well after 
adjustment for selection for coronary angiography specifically in the initial medical 
stabilization group since patients in the early revascularization group underwent cardiac 
catheterization by assignment (P < 0.001), one-year mortality was similar for the two studies 
combined (hazard ratio SHOCK versus SMASH 0.87, 95% confidence interval 0.61, 1.25, P 
= 0.45).
The pooled analysis is demonstrated in Figures 2 and 3. There was no statistically significant 
benefit of early revascularization compared with initial medical stabilization in the overall 
cohort at 30 days (relative risk 0.85, 95% confidence interval 0.71–1.02; Figure 2), while the 
relative risk of death indicated a protective effect of early revascularization compared with 
initial medical stabilization at one year (relative risk 0.82, 95% CI: 0.70–0.96; Figure 3). 
However, there was no significant difference in the treatment effect of early 
revascularization by age cohort at one year (interaction treatment effect by age P = 0.10; 
Figure 3).
Discussion
This systematic overview of RCT in CS complicating acute myocardial infarction is 
important for two reasons: First, it affords the opportunity to examine further the treatment 
effect in patients >75 years of age, and second, it clearly demonstrates the beneficial effect 
of early revascularization across a wide clinical spectrum.
SHOCK was a landmark trial demonstrating the beneficial effect of early revascularization 
in patients with acute myocardial infarction complicated by CS. However, despite its clear 
results regarding mortality at six months (15), one year (29), and six years (30), the study 
was negative regarding its primary endpoint, i.e. 30-day mortality (15). Other attempted 
trials investigating the effect of early revascularization in CS patients were not completed 
(13,14,16) and remained negative (16). While overall benefit was clearly demonstrated in 
SHOCK, uncertainty remained regarding the effect of early revascularization in patients >75 
years of age, where results were conflicting. Although the SHOCK trial showed no effect in 
the elderly (31), the non-randomized SHOCK registry demonstrated a benefit in this age 
group (18). This discrepancy was explained by between group imbalances in ejection 
fraction for the elderly (31). However, this pooled analysis supports the concept that the 
SHOCK trial findings for the elderly were likely a chance finding as evidenced by 
heterogeneity between the trials for the elderly. The fact that there was no significant 
interaction between age and treatment effect supports the notion that early revascularization 
is beneficial in the elderly, but no firm conclusions derived from this pooled analysis 
regarding early revascularization can be drawn in this age group. Current guidelines 
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recommend an early invasive strategy in selected patients >75 years of age (17). 
Accordingly, registries have reported benefit when approximately 30% of the elderly are 
selected for an invasive management strategy (32–36). Specifically, Iakobishvili et al. 
reported results from 549 patients from the Euro Heart Survey and showed a beneficial 
effect of early revascularization in the total population but a blunted effect of an invasive 
approach in patients ≥75 years of age (odds ratio 0.90, 95% CI: 0.41–2.01) (35). Dauerman 
et al. reported results from 310 patients ≥65 years of age from the Worcester population and 
showed an increased use of early revascularization over the decade 1986 to 1997 with a 
decrease in 30-day mortality from 80% to 69% (P = 0.03) (33). Berger et al. reported results 
form 600 patients ≥65 years of age form the Cooperative Cardiovascular Project database 
and showed that 30-day mortality is not different when patients are admitted to hospitals 
with versus without revascularization capabilities (odds ratio 0.83, 95% CI: 0.47, 1.45) (32).
Furthermore, our findings suggest that early revascularization is beneficial across the 
spectrum of severity of illness, despite the high mortality rates with intervention for the most 
severely ill. Although both analyzed trials were performed with similar designs among 
patients with complicated myocardial infarction, the differences in inclusion criteria resulted 
in a sample with a wide range of risk profiles. While SHOCK enrolled patients with a 
median of 5.5 h after acute myocardial infarction with a systolic blood pressure of less than 
90 mmHg or supportive measures to maintain 90 mmHg, SMASH enrolled sicker patients 
with a median of 3.9 h after acute myocardial infarction with a systolic blood pressure of 90 
mmHg or less despite inotropic support. The subsequent clinical picture was a wide range in 
the severity of CS where early revascularization was beneficial. Multivariate modeling 
demonstrated that both at-presentation disease severity and selection for coronary 
angiography in the initial medical stabilization group were responsible for differences in 
outcome between the trials.
Finally, the fact that only two published randomized clinical trials investigating early 
revascularization in CS were identified underscores the notion that enrollment is especially 
arduous in the critically ill where consent is difficult to obtain. Variability in local 
regulations regarding surrogate consent contributes to the substantial challenge (1). TACS 
and HEROICS were not able to recruit a useful number of patients (13,14), while SMASH 
was stopped prematurely after enrolling only 50% of the planned sample size (16). As an 
exception to this rule, other investigators succeeded in enrolling almost 400 patients in an 
RCT of persistent CS recently (36).
Limitations
This pooled analysis consists of only two trials. This number is formally the minimal 
number required to perform such an analysis, and individual patient data were used 
increasing its statistical weight. Moreover, the small number of trials is an important finding 
emphasizing a known problem in clinical research. However, the limited number of patients 
in SMASH might somewhat decrease the ability to detect differences in treatment effect 
between the two trials. Therefore, the lack of statistical significance of the effect of early 
revascularization at 30 days may be due to limited power, although an event reduction of 
15% may be clinically relevant to most people. In addition, 9 (3%) of all randomized 
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patients were excluded to this analysis since they did not suffer from cardiogenic shock due 
to left ventricular failure. Since the primary aim of this analysis was to explore the effect of 
early revascularization in a broad clinical spectrum of cardiogenic shock patients suffering 
from left ventricular failure and not from other reasons, we tried to exclude all possible 
confounders that could obscure the result. Finally, since the current analysis is a systematic 
overview of two RCT only and not the result of an RCT itself, the results do not exhibit the 
same level of evidence.
Conclusion
This is the first and hitherto only pooled analysis in CS complicating acute myocardial 
infarction. Early revascularization results in improved one year survival across the whole 
spectrum of CS severity. In the elderly, early revascularization appears to be of use for 
selected patients, although its effect was not significant in this age cohort. The fact that only 
two randomized clinical trials were identified emphasizes how difficult it is to enroll 
critically ill patients in randomized trials.
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Figure 1. 
Study selection for early revascularization versus initial medical stabilization in cardiogenic 
shock.
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Figure 2. 
Forest plots for 30-day mortality.
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Figure 3. 
Forest plots for 1-year mortality.
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Table I
Randomized controlled trials in cardiogenic shock.
Acronym Design Inclusion criteria Time requirements Treatment arms 1° Endpoint 2° Endpoints n
SMASH (24) Multicenter RCT Myocardial 
infarction Systolic 
blood pressure 
≤90 mmHg 
despite inotropic 
support and 
volume therapy 
PCWP >15 
mmHg CI <2.2 
L/min/m2
Shock ≥30 min 
prior to 
randomization 
Myocardial 
infarction <48 h 
prior to 
randomization
Early 
revascularization 
Initial medical 
stabilization
Death at 30 
days
Non-emergency 
PTCA/CABG 
during 
hospitalization 
CCS/ NYHA 
class at discharge 
Death, cardiac 
events and 
functional status 
at 1 year
55 (54a)
SHOCK (23) Multicenter RCT Myocardial 
infarction Systolic 
blood pressure 
<90 mmHg or 
supportive 
measures to 
maintain ≥90 
mmHg PCWP 
≥15 mmHg CI 
≤2.2 L/min/m2 
Endorgan 
hypoperfusion
Shock ≥ 30 min and 
≤12 h prior to 
randomization 
Myocardial 
infarction ≤36 h 
prior to CS
Early 
revascularization 
Initial medical 
stabilization
Death at 30 
days
In-hospital death, 
death at 6 
months and 1 
year, and 
extended follow 
up (up to 11 
years, 6 year 
average) 
Echocardiograpic 
parameters 
Quality of life
302 (294a)
SMASH, Swiss multicenter evaluation of early angioplasty for shock following myocardial infarction; SHOCK, Should we revascularize occluded 
coronaries for cardiogenic shock?; RCT, randomized controlled trial; PCWP, pulmonary capillary wedge pressure, CI, cardiac index; PTCA, 
percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass graft ; CCS, Canadian Cardiovascular Society; NYHA, New York 
Heart Association.
a
Patients with left ventricular dysfunction only
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Table II
Baseline, hemodynamic and angiographic characteristics and treatment for SHOCK and SMASH patients.
Total (n = 348) SHOCK (n = 294) SMASH (n =54) Pa
Age (years) 65.7 ± 10.2 65.8 ± 10.4 65.4 ± 9.1 0.775
Male 67.8 68.0 66.7 0.875
History of hypertension 45.3 7.6 32.7 0.0504
History of diabetes 29.4 31.3 19.2 0.098
History of hypercholesterolemia 33.0 38.3 17.7 0.009
Current smoking 55.8 54.3 63.5 0.284
History of congestive heart failure 9.1 5.9 26.4 <0.001
Prior myocardial infarction 33.3 33.0 35.2 0.755
Prior percutaneous coronary intervention 7.3 7.6 5.6 0.779
Prior coronary artery bypass graft surgery 6.6 6.1 9.3 0.376
Pulmonary edema on chest X-ray 64.8 68.2 44.9 0.003
Median initial creatinine (mg/dl) (Q1, Q3) 1.30 (1.03, 1.80) 1.30 (1.00, 1.70) 1.34 (1.09, 1.98) 0.227
Anterior MI 58.8 60.2 50.0 0.207
Median time MI to CS (hrs) (Q1, Q3) 5.5 (2.0, 14.5) 5.5 (2.3, 14.1) 3.9 (1.0, 14.8) 0.164
Median time from randomization to death (Q1, Q3) 40.2 (7.0, 173.3) 48.5 (8.8, 176.3) 10.3 (2.4, 71.3) 0.032
Median time from CS to death (Q1, Q3) 45.5 (11.3, 178.2) 51.7 (15.3, 184.9) 16.7 (6.9, 75.3) 0.026
Hemodynamic datab
  Heart rate (bpm) 102.1 ± 23.7 101.9 ± 22.6 103.6 ± 29.2 0.670
  Systolic blood pressure (mmHg) 86.2 ± 19.7 88.0 ± 20.4 76.7 ± 11.5 <0.001
  Diastolic blood pressure (mmHg) 53.2 ± 15.5 54.7 ± 15.9 45.9 ± 11.3 <0.001
  Pulmonary capillary wedge pressure (mmHg) 24.3 ± 7.3 24.3 ± 7.4 23.6 ± 6.0 0.739
  Cardiac index (L/min/m2) 1.79 ± 0.60 1.79 ± 7.37 1.70 ± 0.27 0.384
  Left ventricular ejection fraction 30.5 ± 11.9 30.4 ± 11.9 31.6 ± 12.4 0.664
Angiography (n = 275, 241, 34)
  Number of diseased vessels 0.233
  0 2.2 2.1 2.9
  1 10.9 11.2 8.8
  2 24.3 21.9 41.2
  3 62.5 64.8 47.1
  Culprit vessel 0.322
  Left main 6.7 5.4 14.7
  Left anterior descending 49.0 50.2 41.2
  Right coronary artery 28.6 29.0 26.5
  Left circumflex 12.5 12.2 14.7
  Saphenous vein graft 3.1 3.2 2.9
  Left main stenosis ≥70% 12.2 10.8 23.3 0.070
Treatment
  Vasopressors/inotropic agents 99.4 100 96.3 0.024
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Total (n = 348) SHOCK (n = 294) SMASH (n =54) Pa
  Thrombolysis 52.6 55.8 35.2 0.007
  Intra-aortic balloon counterpulsation 74.4 86.7 7.4 <0.001
  Percutaneous transluminal coronary angioplasty 37.9 34.7 55.6 0.006
  Stents 14.0 14.0 16.7 0.599
  Coronary artery bypass graft surgery 15.5 18.4 0 <0.001
SMASH, Swiss multicenter evaluation of early angioplasty for shock following myocardial infarction; SHOCK, Should we revascularize occluded 
coronaries for cardiogenic shock?; MI, myocardial infarction; CS, cardiogenic shock; Q1, Q3, interquartile range.
All variables are % unless indicated otherwise.
aStudent's t-test for normally distributed continuous variables, the Wilcoxon rank-sum test for non-normally distributed continuous variables, 
Fisher's exact test and χ2 test for categorical variables.
bObtained while on support measures.
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